Asunto(s)
Contaminantes Atmosféricos/toxicidad , Melanoma/inducido químicamente , Hidrocarburos Policíclicos Aromáticos/toxicidad , Neoplasias Cutáneas/inducido químicamente , Contaminantes Atmosféricos/metabolismo , Humanos , Hidrocarburos Policíclicos Aromáticos/metabolismo , Datos Preliminares , Factores de RiesgoRESUMEN
Psoriasis is a chronic inflammatory skin disease affecting 2-3% of the population in the world. The scalp is the most common, and frequently the first site of disease involvement. Occasionally it may be the only localization of psoriasis. Treatment of scalp psoriasis is often unsatisfactory, due to limited available topical therapy and reduced efficacy of some systemic drugs. Biologic therapies are recommended for severe psoriasis, resistant to topical treatment, but evidence from randomized, controlled studies is lacking regarding effectiveness on scalp-localized lesions. Several clinical studies have shown the efficacy of secukinumab on plaque psoriasis, and some encouraging experience suggest the use in difficult sites such as the scalp; this article reports effective treatment with secukinumab of a series of patients with plaque and scalp psoriasis.